Article Text

Download PDFPDF
Biologic discontinuation studies: a systematic review of methods; comment on the article by Yoshida et al
  1. Aatke van der Maas,
  2. Noortje van Herwaarden,
  3. Alfons A den Broeder
  1. Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands
  1. Correspondence to Aatke van der Maas, Rheumatology, Sint Maartenskliniek, Nijmegen 6500 GM, The Netherlands; a.vandermaas{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Yoshida et al present an overview of different designs and ‘failure definitions’ in biologic discontinuation studies in rheumatoid arthritis (RA).1 We feel it is a very important review, as the number of discontinuation studies is increasing and, therefore, awareness of the heterogeneity in these study designs as demonstrated in this review is essential. We have, however, a few comments. First, one of the difficulties in interpreting discontinuation studies is that different protocols can be used, discontinuation protocol or dose-tapering protocols, and that interpretation is sometimes not straightforward. This is exemplified by …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles